493 related articles for article (PubMed ID: 23696234)
1. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
2. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.
Cawson MR; Mitchell SA; Knight C; Wildey H; Spurden D; Bird A; Orme ME
BMC Musculoskelet Disord; 2014 Jan; 15():26. PubMed ID: 24444034
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
4. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
[TBL] [Abstract][Full Text] [Related]
5. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
[No Abstract] [Full Text] [Related]
6. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis.
Egilman AC; Kesselheim AS; Avorn J; Raymakers AJN; Rome BN
JAMA Dermatol; 2024 Apr; 160(4):409-416. PubMed ID: 38381418
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.
Avgerinou G; Bassukas I; Chaidemenos G; Katsampas A; Kosmadaki M; Kousoulakou H; Petridis A; Schenkel B; Sotiriadis D; Spiliopoulos T; Stavropoulos P; Toumpi E; Xaplanteris L
BMC Dermatol; 2012 Jul; 12():10. PubMed ID: 22831458
[TBL] [Abstract][Full Text] [Related]
8. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.
Atalay S; van den Reek JMPA; van Vugt LJ; Otero ME; van de Kerkhof PCM; den Broeder AA; Kievit W; de Jong EMGJ
BMC Dermatol; 2017 May; 17(1):6. PubMed ID: 28482858
[TBL] [Abstract][Full Text] [Related]
9. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
Nyholm N; Schnack H; Danø A; Skowron F
Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
[TBL] [Abstract][Full Text] [Related]
10. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Warren RB; See K; Burge R; Zhang Y; Brnabic A; Gallo G; Garrelts A; Egeberg A
Dermatol Ther (Heidelb); 2020 Feb; 10(1):73-86. PubMed ID: 31686337
[TBL] [Abstract][Full Text] [Related]
11. Immunologic biomarkers for clinical and therapeutic management of psoriasis.
Cordiali-Fei P; Bianchi L; Bonifati C; Trento E; Ruzzetti M; Francesconi F; Bultrini S; D'Agosto G; Bordignon V; Francavilla V; Tripiciano A; Chiricozzi A; Campione E; Cavallotti C; Orlandi A; Berardesca E; Di Carlo A; Chimenti S; Ensoli F
Mediators Inflamm; 2014; 2014():236060. PubMed ID: 25136144
[TBL] [Abstract][Full Text] [Related]
12. Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients.
Bardazzi F; Bigi L; Campanati A; Conti A; Di Lernia V; Di Nuzzo S; Kaleci S; Lasagni C; Offidani AM; Giacchetti A; Nicolini M; Bettacchi A; Rosa L; Sacchelli L
Eur J Dermatol; 2020 Apr; ():. PubMed ID: 32266875
[TBL] [Abstract][Full Text] [Related]
13. Evolving Landscape of Biologic Therapy for Pediatric Psoriasis.
Do H; Babbush Graber K; Chernoff KA; Melnick LE
Dermatol Clin; 2024 Jul; 42(3):377-386. PubMed ID: 38796269
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real-life data from the BiPe cohorts.
Hanafi B; Beauchet A; Di Lernia V; Lasek A; Severino-Freire M; Barbarot S; Hadj-Rabia S; Phan A; Bursztejn AC; Maruani A; Chaby G; Quiles-Tsimaratos N; Phan C; Zitouni J; Mazereeuw-Hautier J; Mahé E;
Pediatr Dermatol; 2023; 40(5):835-840. PubMed ID: 37442765
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
[TBL] [Abstract][Full Text] [Related]
16. Successful secukinumab treatment of generalized pustular psoriasis.
Guo HS; Zhou XL; Chen HH; Hu T; Liu MH; Liu FY; Ma LL; Li WQ
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762856
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial.
Prinsen CA; Spuls PI; Sprangers MA; de Rie MA; Legierse CM; de Korte J
Trials; 2012 Dec; 13():236. PubMed ID: 23216943
[TBL] [Abstract][Full Text] [Related]
18. Impact of residual skin lesions and previous biologic treatment failure on patient-reported outcomes in patients with psoriasis receiving biologic treatment.
Song WJ; Yoon HS
J Dermatol; 2024 Jun; 51(6):772-778. PubMed ID: 38660957
[TBL] [Abstract][Full Text] [Related]
19. Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Navarro Ruiz A; Toledo Alberola F; Aceituno S;
Farm Hosp; 2024; 48(2):51-56. PubMed ID: 37739901
[TBL] [Abstract][Full Text] [Related]
20. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Warren RB; Zhong Y; Zhuo J; Cichewicz A; Kadambi A; Junqueira D; Westley T; Kisa R; Daamen C; Augustin M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2839-2857. PubMed ID: 37801281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
